MMAF-sodium-Monomethylauristatin-F-sodium-DataSheet-生命科学试剂-MedChemExpress

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemEMMAFsodiumCat.No.:HY-15579BCASNo.:1799706-65-2Synonyms:MonomethylauristatinFsodium分⼦式:C₃₉H₆₄N₅NaO₈分⼦量:753.94作⽤靶点:Microtubule/Tubulin;ADCCytotoxin作⽤通路:CellCycle/DNADamage;Cytoskeleton;Antibody-drugConjugate/ADCRelated储存⽅式:4°C,protectfromlight,storedundernitrogen*该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤。溶解性数据体外实验DMSO:≥200mg/mL(265.27mM)*"≥"meanssoluble,butsaturationunknown.MassSolvent1mg5mg10mgConcentration制备储备液1mM1.3264mL6.6318mL13.2637mL5mM0.2653mL1.3264mL2.6527mL10mM0.1326mL0.6632mL1.3264mL请根据产品在不同溶剂中的溶解度，选择合适的溶剂配制储备液；该产品在溶液状态不稳定，建议您现⽤现配，即刻使⽤.体内实验请根据您的实验动物和给药⽅式选择适当的溶解⽅案。以下溶解⽅案都请先按照InVitro⽅式配制澄的储备液，再依次添加助溶剂：(为保证实验结果的可靠性，澄的储备液可以根据储存条件，适当保存；体内实验的⼯作液，建议您现⽤现配，当天使⽤；以下溶剂前显⽰的百分⽐指该溶剂在您配制终溶液中的体积占⽐；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的⽅式助溶)1.请依序添加每种溶剂：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥5mg/mL(6.63mM);Clearsolution1/2MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE2.请依序添加每种溶剂：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥5mg/mL(6.63mM);Clearsolution3.请依序添加每种溶剂：10%DMSO>>90%cornoilSolubility:≥5mg/mL(6.63mM);ClearsolutionBIOLOGICALACTIVITY⽣物活性MMAFsodium(MonomethylauristatinFsodium)⼀种有效的微管蛋⽩聚合(tubulinpolymerization)抑制剂，⽤作抗肿瘤药物。MMAFsodium(MonomethylauristatinFsodium)⼴泛⽤作抗体偶联药物(ADCs)的细胞毒性成分，如Vorsetuzumabmafodotin和SGN-CD19A。IC50&TargetAuristatin体外研究MMAFinhibitsanaplasticlargecelllymphomaKarpas299,breastcarcinomaH3396,renalcellcarcinoma786-OandCaki-1cellswithIC50sof119,105,257and200nMinvitrocytotoxicityassay[4].户使⽤本产品发表的科研⽂献•JControlRelease.2018May10;277:48-56.•MolTherNucleicAcids.2018Mar2;10:227-236.•TargetOncol.2019Oct;14(5):577-590.•OncolRep.2020Dec9.•UniversityofMinnesota.2022Sep.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].DoroninaSO,etal.EnhancedactivityofmonomethylauristatinFthroughmonoclonalantibodydelivery:effectsoflinkertechnologyonefficacyandtoxicity.BioconjugChem.2006Jan-Feb;17(1):114-24.[2].LeeJW,etal.EphA2targetedchemotherapyusinganantibodydrugconjugateinendometrialcarcinoma.ClinCancerRes.2010May1;16(9):2562-70.[3].LeeJJ,etal.Enzymaticprenylationandoximeligationforthesynthesisofstableandhomogeneousprotein-drugconjugatesfortargetedtherapy.AngewChemIntEdEngl.2015Oct5;54(41):12020-4.[4].KimEG,etal.StrategiesandAdvancementinAntibody-DrugConjugateOptimizationforTargetedCancerTherapeutics.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplicatio